$GH

BTIG raised its price target for Guardant Health (GH) to $210 from $195, citing strong growth outlook. The firm expects Q3 revenue to exceed estimates by 4%, with Shield volume up 258% YoY. GH's stock has risen 144.53% in the past year, currently trading at $173.25. The company reported Q2 revenue of $335M, up 44% YoY, and raised its full-year guidance.

Analysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.

Wall Street analyst research calls for Friday include upgrades for Hess Midstream LP (HESM) to Outperform, MSC Industrial (MSM) to Overweight, and SpaceX (SPCX) to Buy. Downgrades include Deckers Outdoor (DECK) to Underweight, Globe Life (GL) to Neutral, and NVR (NVR) to Underperform. Initiations include Guardant Health (GH) and Natera (NTRA) with Buy ratings. Markets saw declines, with Nasdaq down 2.6% and Treasury yields dropping sharply.

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

Guardant Health's challenge to a DNA sequencing patent held by TwinStrand Biosciences and the University of Washington was rejected by the US Patent and Trademark Office. The patent, U.S. Patent No. 10,760,127, covers methods of reducing errors in DNA sequencing. This decision may impact Guardant Health's operations and intellectual property strategy.

Labcorp and other testing & diagnostics services stocks reported Q2 earnings. RadNet (RDNT) reported $622.7M revenue, up 25% YoY, but stock is down 8%. NeoGenomics (NEO) reported $201.7M revenue, up 11.2%, and stock is up 26.4%. Quest (DGX) reported $3.04B revenue, up 10.2%, and stock is up 11.3%. Guardant Health (GH) reported $335M revenue, up 44.3%, and stock is up 6%.

Guardant Health reported data showing its Shield blood test improved CRC screening adherence and prevented more deaths in simulations compared to stool tests, with 99% adherence in two rural clinics. The company aims to expand into population screening, pending payer coverage and guideline updates.

Analysts updated ratings and price targets for several companies. Albemarle (ALB) was upgraded to buy with a $130 target by Mizuho. Dell (DELL) and Domino's (DPZ) were downgraded by Barclays and Gordon Haskett, respectively. Other notable changes include upgrades for Galaxy Digital (GLXY) and Trane (TT), and downgrades for Carrier (CARR), Lennox (LII), and more. Price targets were adjusted accordingly.

GRAIL (GRAL) and Guardant Health (GH) both sell cancer-detection blood tests. GH has higher revenue ($1.18B vs $165M), growth (44.30% vs 25.70%), and market cap ($22.59B vs $5.94B), but GRAL has more cash ($861.61M vs $1.05B) and less debt ($91.31M vs $1.70B). Both lack earnings, with GRAL at $133 and GH at $168 as of October 7.

Guardant Health (GH) received EU approval for Guardant360 CDx, a companion diagnostic for AstraZeneca's camizestrant in ER+, HER2- advanced breast cancer. This follows prior approvals in the U.S. and Japan, expanding its liquid biopsy CDx reach. Investors may watch for EU uptake, reimbursement, and revenue impact.